יום ראשון, 5 באוקטובר 2014


Israeli company offers cure for Ebola

Protalix says it has the resources to produce experimental medicine ZMapp, which has run out elsewhere
The death toll from the Ebola epidemic has climbed above 2,000, the World Health Organisation (WHO) said Friday, as it voiced hopes a vaccine could be available in November.
AFP"Ebola in West Africa"AFP
However, supplies of experimental medicines -- including the prototype drug ZMapp -- are limited, and "will not be sufficient for several months to come," the World Health Organisation (WHO) warned Friday.
Protalix, an Israeli biopharmaceutical company, said Saturday that it has the resources to produce the coveted ZMapp, which has recently run out, Israeli site The Times of Israel, citing Channel 2 TV's report, said Sunday.
In an interview with Channel 2, Dr. Yossi Shaaltiel, the executive vice president of research and development at Protalix, said: “Today our production capacity exceeds our needs, and we would certainly be happy to have the company producing the Ebola drug have us produce the drug for them. We would know how to do it effectively, in large quantities, and in a relatively short period of time.”
ZMapp has been given to about 10 infected health workers, including Americans and Europeans, of whom three recovered. WHO assistant director general Marie-Paule Kieny told reporters "there is not enough experience with ZMapp to conclude whether this treatment works or not," adding "there seem to be encouraging signs."
When the company started out, Shaaltiel said, “We were considered crazy.”
“Now we are proving that we are the only ones working with the [kind of] plants that [are developed into] pharmaceutical drugs which are approved,” he said.
According to the UN health organization's data, the deadly Ebola virus has claimed 2,097 lives out of 3,944 people infected in Liberia, Guinea and Sierra Leone, since emerging last December.



Israelis test gold-plated ‘cardiac patch’ to treat heart attacks

Researchers hope ‘cardiac patch’ powered by nano-gold can reverse damage from heart attacks for first time


 October 2, 2014, 



shutterstock_113719291
The only treatment for advanced heart disease today is a transplant (photo credit: Heart image)

יום רביעי, 1 באוקטובר 2014

A cure for ALL cancers is on the way as Israeli scientists make major breakthrough


MILLIONS of cancer ­sufferers have been given fresh hope of a cure after ground-breaking research.


6


By: Giles Sheldrick

.The breakthrough came in a 16-year study of the only ­animal immune to cancer 

  .The discovery by an Israeli specialist was last night hailed as “radical and potentially life-changing
In a world first, Professor Aaron Avivi and his team found that cells from the blind mole rat       and its cousin the naked mole rat secrete a substance that destroys cancer cells in mammals – including humans.    Experts think harvesting this substance and making it safe to digest could wipe out a disease that kills eight million people each year worldwide. Last night Prof Avivi, of Haifa University in Israel was heading to London where he is due  to present his findings to professionals.   His radical approach studied the two species of rat that both live mostly underground – which the team discovered had led to a dramatic evolution of their metabolism.
Blind mole rats outlive other rodents by at least 20 years with no outward signs of ageing. Researchers have never located a cancerous tumour on one of them.Millions of cancer sufferers are given fresh hope for a cure [picposedby model GETTY]
The team tested the underground rodents and regular mice and rats with two potent carcinogens. Ordinary mice and rats developed tumours – none was found in the subterranean rats.     The study, published in the widely respected BMC Biology Journal, concluded: “Blind mole rats are resistant to spontaneous cancer but also to experimentally induced cancer.
“It shows the unique ability of the blind mole rat to inhibit growth and kill cancer cells, but not normal cells. It has evolved efficient anti-cancer mechanisms. Exploring the molecular mechanisms may hold the key for understanding the nature of resistance to cancer and identify new strategies for treating humans. The study was described as “exciting” by Prof Penella Woll, of the University of Sheffield’s department of oncology. She said: “Other researchers have taken a similar approach, studying sea creatures with intrinsic cancer resistance to develop the anti-cancer drug ­trabectedin – so we know that this can succeed

Cancer care specialist Prof Sam Ahmedzai said: “If Prof Avivi’s research can help us identify what genetic changes have occurred in the blind mole rat – and if that knowledge can allow us to modify humans’ genetic codes – then this is a radically and potentially life-saving treatment.

יום חמישי, 18 בספטמבר 2014

BEN GURION UNIVERSITY -  first Israeli university to become member of US National Academy of Inventors
 
 
 
The Beersheba institution of higher learning was recognized as being one of the 100 leading universities in the world for the number of applied US patents. Students
Students at Hebrew University. (photo credit:MARC ISRAEL SELLEM/THE JERUSALEM POST)
             
            

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Israeli researchers: Not so fast on artificial sweetener settled science

 
Find artificial sweeteners boost diabetes risk — Will anti-Israel academic boycotters ignore these
findings?
     
Posted by    Thursday, September 18, 2014     

 
http://www.wpxi.com/videos/news/artificial-sweetener-could-promote-diabetes/vCsRgB/

It’s a good thing we still have scientists who refuse to accept settled science and scientific consensus, and keep on digging and questioning prevailing wisdoms.
It seems that many of such scientists are in Israel, perhaps because politicized scientific conformity is not as prized in the “start-up nation” as it is in Euorpe and the U.S.

One example from Israel we reported on previously was Nobel Prize in Chemistry awarded scientific denier:
Israeli scientist Daniel Shechtman won the 2011 Nobel Prize in chemistry on Wednesday for his discovery of quasicrystals, a mosaic-like chemical structure that researchers previously thought was impossible.
The Royal Swedish Academy of Sciences said Shechtman’s discovery in 1982 fundamentally changed the way chemists look at solid matter. It initially faced strong objections from the scientific community, and even got him kicked out of his research group in the United States.
Now another, from AFP via Times of Israel, Sweeteners boost diabetes risk, Israeli study finds:

Promoted as an aid to good health, artificial sweeteners may in fact be boosting diabetes risk, said an Israeli study Wednesday that urged a rethink of their widespread use and endorsement….
After leaving a sensation of sweetness on the tongue, NAS [Non-caloric artificial sweeteners] molecules pass through the intestinal tract without being absorbed.
This explains why, unlike sugar, they add negligibly, if at all, to the calorie count.
But Israeli scientists reported in the journal Nature that experiments on lab mice and a small group of humans found NAS disrupted the makeup and function of gut bacteria, and actually hastened glucose intolerance.
“Artificial sweeteners were extensively introduced into our diets with the intention of reducing caloric intake and normalizing blood glucose levels without compromising the human ‘sweet tooth,’” the paper said.
“Our findings suggest that NAS may have directly contributed to enhancing the exact epidemic that they themselves were intended to fight,” it said bluntly.
Scientists led by Eran Elinav and Eran Segal of the Weizmann Institute of Science in Israel added three commonly-used types of NAS — aspartame, sucralose or saccharin — to the drinking water of mice in body-size appropriate doses equivalent to recommended maximum human intake.

Oh, and one more thing.
The Weizmann Institute of Science is subject to the academic boycott of Israel championed by Steven Salaita, the controversial almost-U. Illinois professor and his supporters at the American Studies Association and in some pockets of academia.
http://commons.wikimedia.org/wiki/File:Weizmann_Institute_of_Science40.JPG
[Weizmann Institute of Science via Wikimedia Commons]
The academic BDS supporters should ignore these Israeli research findings, in the spirit of anti-Zionist solidarity.

יום שני, 1 בספטמבר 2014

Israeli IPO’s World-Beating 73% Surge Leads August Rally
 
 
Mobileye has surged 73 percent to $43.22 since listing in New York on July 31, the biggest rally among all companies globally that raised $500 million or more in the past three months. Caesarstone Sdot-Yam Ltd. (CSTE), the maker of quartz counter-tops, climbed 20 percent in August, the second-best performance on the Bloomberg Israel-U.S. Equity Index, which rose 4.8 percent.
While signs have emerged that the Gaza fighting is starting to curb output at some Israeli businesses, hurt tourism and cut into consumer spending, investors have shown little concern, instead bidding up stocks in line with gains being posted in the U.S. and other major global markets. The performance of Mobileye and Caesarstone, which has more than tripled since its 2012 listing, could help bolster demand for more Israeli initial public offerings, according to Josef Schuster, the founder of Chicago-based IPOX Schuster LLC.
“Momentum drives everything right now,” Schuster said by phone Aug. 28. “Mobileye and Caesarstone, if you held that, you made a lot of money.”
The Nasdaq Composite Index (CCMP) advanced 4.8 percent this month, while the Standard and Poor’s 500 Index gained 3.8 percent, breaking the 2,000 mark on Aug. 26, 27 and 29.
Investors are pouring money into equities on optimism the U.S. economy is strengthening and as European Central Bank President Mario Draghi signaled policy makers may introduce an asset-buying plan to bolster growth amid slowing inflation.

Record IPO

Executives at Mobileye didn’t respond to a request for comment made after business hours in Israel.
Mobileye’s $1 billion IPO was the biggest in the U.S. by an Israeli company on record, part of a rush of deals last month. Six Israeli companies have gone public in the U.S. this year, according to data compiled by Bloomberg. Eight more have offerings pending.
“We’re continuing to see moderate appetite for IPOs in the U.S. by Israeli companies,” Phyllis Korff, a lawyer at Skadden Arps, Slate, Meagher & Flom LLP in New York, said in an e-mail. “This activity could continue through the end of 2014 and into the first quarter of 2015,” said Korff, who worked on the Mobileye offering.
The Jerusalem-based technology company, whose customers include luxury electric-carmaker Tesla Motors Inc., posted 2013 net income of $19.9 million following two years of losses, according to its IPO prospectus. Revenue in 2013 was $81.2 million, more than double the figure from 2012.

Rate Cut

“People are buying it on the hope of great growth,” Brian Krawez, who oversees $3 billion at Scotts Valley, California-based Scharf Investments, said by phone Aug. 28. “People were very skeptical of the stock market, they missed a lot of the rally. Now with the market up, they’re moving cash from the sidelines.”
While global financial markets have shrugged off fighting in Gaza, it has begun to take its toll on Israel’s economy. The Bank of Israel unexpectedly cut interest rates to a record low on Aug. 25 in an attempt to boost an economy already hit by slowing exports.
Israeli growth slowed in the second quarter to 1.7 percent from 2.8 percent in the previous three months, as exports, which account for about a third of the economy, tumbled 18 percent, according to official data released Aug. 17.

Stock Gains

An Egyptian-brokered truce that started Aug. 26 halted seven weeks of fighting that killed more than 2,100 Palestinians and 70 on the Israeli side, according to official tallies.
The local TA-25 Index (TA-25) rose 0.6 percent this month, trailing the 4.8 percent gain on the Bloomberg Israel-US Index. Tel Aviv stocks have appreciated 5.3 percent this year, compared with an 11 percent advance for U.S.-listed Israeli stocks.
Caesarstone, which makes quartz kitchen counter-tops, surged this month after issuing a new full-year sales estimate that surpassed analysts’ projections. The stock has appreciated 373 percent since its IPO in March of 2012.
“They’re just executing extremely well and the stock was cheap at the onset,” Schuster said. “It’s one of those stocks you wish you had held on to forever.” ((An earlier version of this story corrected the law firm’s name in the ninth paragraph.)) 
 
 

יום שבת, 30 באוגוסט 2014

GOOD NEWS FROM TINNY ISRAEL FOR RELIEF OF MILLIONS  PEOPLE WORLDWIDE

Came from Haifa University,  Israel

EXCLUSIVE: A cure for ALL cancers is on the way as scientists make major breakthrough

MILLIONS of cancer ­sufferers have been given fresh hope of a cure after ground-breaking research.

Scientists have made huge leaps in cancer research
Scientists have made huge leaps in cancer research [picposedbymodel REUTERS]

The breakthrough came in a 16-year study of the only ­animal immune to cancer.
The discovery by an Israeli specialist was last night hailed as “radical and potentially life-changing”.
In a world first, Professor Aaron Avivi and his team found that cells from the blind mole rat and its cousin the naked mole rat secrete a substance that destroys cancer cells in mammals – including humans.
Experts think harvesting this substance and making it safe to digest could wipe out a disease that kills eight million people each year worldwide. Last night Prof Avivi, of Haifa University in Israel was heading to London where he is due  to present his findings to professionals.
His radical approach studied the two species of rat that both live mostly underground – which the team discovered had led to a dramatic evolution of their metabolism.
Blind mole rats outlive other rodents by at least 20 years with no outward signs of ageing. Researchers have never located a cancerous tumour on one of them.
cancer
Millions of cancer sufferers are given fresh hope for a cure [picposedby model GETTY]

The team tested the underground rodents and regular mice and rats with two potent carcinogens. Ordinary mice and rats developed tumours – none was found in the subterranean rats.
The study, published in the widely respected BMC Biology Journal, concluded: “Blind mole rats are resistant to spontaneous cancer but also to experimentally induced cancer.
“It shows the unique ability of the blind mole rat to inhibit growth and kill cancer cells, but not normal cells. It has evolved efficient anti-cancer mechanisms.
“Exploring the molecular mechanisms may hold the key for understanding the nature of resistance to cancer and identify new strategies for treating humans.”
The study was described as “exciting” by Prof Penella Woll, of the University of Sheffield’s department of oncology. She said: “Other researchers have taken a similar approach, studying sea creatures with intrinsic cancer resistance to develop the anti-cancer drug ­trabectedin – so we know that this can succeed.”
Cancer care specialist Prof Sam Ahmedzai said: “If Prof Avivi’s research can help us identify what genetic changes have occurred in the blind mole rat – and if that knowledge can allow us to modify humans’ genetic codes – then this is a radically and potentially life-saving treatment.
“There will undoubtedly be many years of extracting the relevant parts of the mole rats’ genetic differences and then – the most difficult aspect – bringing those gene extracts into humans. Prof Avivi is to be congratulated on opening up an exciting new phase of research.”
Oliver Childs, of Cancer Research UK, added: “It’s a long way off, but it will be interesting to see if further research can find a way to help prevent or treat cancer in humans.”
In Britain, nearly 350,000 people are diagnosed with cancer every year. Macmillan Cancer Support predicts the number who will get cancer during their lifetime will rise to nearly half the UK population by 2020. Other studies forecast global cancer rates will increase to 16 million new cases by the same year.